We recently described a bioinspired material composed of nanoparticulate mineralized collagen glycosaminoglycan (MC-GAG) that induces efficient osteogenic differentiation of human mesenchymal stem cells (hMSCs) without the addition of exogenous growth factors, thereby suggestive of a promising, growth factorfree, materials-based method for clinically utilizable bone regeneration. We have previously reported that MC-GAG scaffolds autogenously induce BMP receptor signaling via the canonical (Smad1/5) pathway. However, the necessary and sufficient components of this mechanism remain unknown. Our current study evaluates the contribution of the non-canonical (MAP kinase) pathway in MC-GAG induced osteogenesis.
METHODS: hMSCs were cultured in osteogenic media on non-mineralized (Col-GAG) and nanoparticulate mineralized (MC-GAG) collagen glycosaminoglycan scaffolds. Scaffolds were untreated or treated with the MAP kinase inhibitor PD98059 at 20 μM and 50 μM for 4 days, 14 days, 24 days, 4 weeks, and 8 weeks. Gene and protein expression were measured using quantitative RT-PCR and western blot analysis. Scaffolds were subjected to histochemical and micro-computed tomographic analyses.
RESULTS:
Inhibition of the non-canonical BMP receptor signaling pathway resulted in a decrease in expression of early osteogenic genes. Western blot analysis demonstrated that PD98059 inhibited phosphorylation of ERK1/2 and JNK without affecting Smad1/5, p38, and Akt phosphorylation. At 4 and 8 weeks of culture, Runx2 protein expression and mineralization on μCT scans were decreased in the presence of PD98059.
CONCLUSION:
Activation of the non-canonical BMP receptor signaling pathway is essential for osteogenic differentiation of hMSCs on MC-GAG scaffolds. 
METHODS:
Full-thickness 6 mm-diameter wounds were excised from the dorsa of C57bl/6 mice, splinted, and inoculated with 3.75 x 10 6 colony forming units (CFU) of MRSA. Mice were randomized into 3 treatment groups: none, 10 minutes or 20 minutes Steri-Lysis TM . They were treated on post-operative days 3, 5, and 7, with aseptic swabbing before and after. On day 7, the wounds were harvested. The right wound was homogenized, serially diluted, plated, incubated and CFU enumerated to quantify the bacterial load per wound. The left wound was processed for histology and immunofluorescence with anti-S. aureus antibody, then imaged with confocal microscopy.
RESULTS: Wounds treated with 3 treatments of 20 minutes Steri-lysis
TM demonstrated a 90% reduction in S. aureus CFU (p = 0.0441) compared to untreated wounds. Efficacy of 20 minutes Steri-lysis TM treatment was confirmed by lack of S. aureus immunofluorescence on wounds. Furthermore, assessment of gross tissue and hematoxylin and eosinstained sections demonstrated no evidence of tissue injury, aberrant architecture, cellular infiltration, inflammation or residue.
CONCLUSION:
This novel treatment system disinfects infected wounds in an in vivo murine model, without evidence of toxicity to the wound or surrounding tissues. Given these results, and the unique germicidal mechanism, NTP holds the promise to treat wounds infected by a wide variety of pathologic organisms, without the risk of developing antibiotic resistance. Steri-lysis TM is an innovative, low cost, portable technology that has the potential to revolutionize device sterilization and shift the paradigm of wound treatment.
